Bart Heeg
AuthID: R-00K-AND
1
TÃTULO: Indirect Treatment Comparison of Daratumumab, Pomalidomide, and Dexamethasone Versus Standard of Care in Patients with Difficult-to-Treat Relapsed/Refractory Multiple Myeloma
AUTORES: He, Jianming; Berringer, Heather; Heeg, Bart; Ruan, Haoyao; Kampfenkel, Tobias; Dwarakanathan, Harikumaran R.; Johnston, Stephen; Mendes, Joao; Lam, Annette; Bathija, Sacheeta; Mackay, Eric;
PUBLICAÇÃO: 2022, FONTE: ADVANCES IN THERAPY, VOLUME: 39, NÚMERO: 9
AUTORES: He, Jianming; Berringer, Heather; Heeg, Bart; Ruan, Haoyao; Kampfenkel, Tobias; Dwarakanathan, Harikumaran R.; Johnston, Stephen; Mendes, Joao; Lam, Annette; Bathija, Sacheeta; Mackay, Eric;
PUBLICAÇÃO: 2022, FONTE: ADVANCES IN THERAPY, VOLUME: 39, NÚMERO: 9
INDEXADO EM: 
Scopus 
WOS
Scopus WOS2
TÃTULO: Indirect Treatment Comparisons of Daratumumab, Pomalidomide, and Dexamethasone Versus Daratumumab, Bortezomib, and Dexamethasone or Bortezomib and Dexamethasone in Patients with Difficult-to-Treat Relapsed/Refractory Multiple Myeloma
AUTORES: He, Jianming; Berringer, Heather; Heeg, Bart; Kampfenkel, Tobias; Dwarakanathan, Harikumaran R.; Johnston, Stephen; Mendes, Joao; Lam, Annette; Bathija, Sacheeta; Mackay, Eric;
PUBLICAÇÃO: 2021, FONTE: BLOOD, VOLUME: 138
AUTORES: He, Jianming; Berringer, Heather; Heeg, Bart; Kampfenkel, Tobias; Dwarakanathan, Harikumaran R.; Johnston, Stephen; Mendes, Joao; Lam, Annette; Bathija, Sacheeta; Mackay, Eric;
PUBLICAÇÃO: 2021, FONTE: BLOOD, VOLUME: 138
INDEXADO EM: WOS
WOS